Denmark's Dako is teaming up with Ono Pharmaceutical to develop a test for Ono and Bristol-Myers Squibb's drug for non-small cell lung cancer, Opdivo, adding to its tally of companion diagnostics partnerships and gaining more ground in the field.
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.
ImmusanT roped in $12 million in Series B financing to beef up development of its companion diagnostic tests and vaccine for celiac disease, giving the company a much-needed boost as it forges ahead with R&D for its product.
A pair of European diagnostics companies have wrapped up venture financings. Autoimmune diagnostician Protagen had a first close of a €10 million ($12.5 million) financing, while cancer genomic diagnostics company, 14M Genomics, a spinout of the Wellcome Trust Sanger Institute, got £12.5 million ($19.6 million).
Singapore's government is teaming up with Thermo Fisher and other heavyweights in the biomedical space to accelerate the development and commercialization of new diagnostic tests.
Hot on the trail of companion diagnostics partnerships, Qiagen is teaming up with pharma bigwig Novartis to develop tests for the company's drug portfolio.
GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with GE Healthcare to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.
In late 2014, the push to develop universal companion diagnostics to facilitate personal treatments for multiple cancers appears to be accelerating.
Diagnostics giant Thermo Fisher Scientific has partnered with GlaxoSmithKline and Pfizer to create a companion diagnostic for solid tumors that will address multiple drug programs. The move is a first step to superseding the often highly fragmented development and use of companion diagnostics to determine the best course of treatment for a particular patient.
The global companion diagnostics market crossed the billion-dollar threshold in 2013 and is continuing to climb rapidly as healthcare systems tap into the value of testing which patients would benefit most from targeted treatments.